Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
This article was originally published in The Tan Sheet
Executive Summary
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good” the firm could actually emerge from the crisis with a stronger reputation, says crisis management expert Gene Grabowski says.
You may also be interested in...
Consumers Need Motivation To Buy Brands Returned To Stores After Absence
Brands returning to store shelves after an absence need to give a “provocative” reason for consumers to purchase the products again, according to an OTC marketing management consultant. The best reasons are product news, such as new formats, packaging innovations and positive pricing.
Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
Omega Pharma will pay $619 million for GSK’s Lactacyd feminine wash products, Abtei supplements, Solpadeine analgesics, Zantac antacid, Nytol sleep aids and the allergy drug Beconase. The deal is part of Glaxo’s plan to simplify its consumer business by selling 19 OTC brands.
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.